SphingoTec GmbH

SphingoTec Announces Management Changes

New Formula Leverages Proenkephalin A 119-159 (penKid) for Improved GFR Estimation in Steady-State and Critically Ill Patients

International Experts Highlight Demand for Diagnostic Innovations as PenKid’s Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools

Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid

SphingoTec’s Innovative IVD Product sphingotest® penKid® Receives First IVDR Certificate

ADQI Group Recognizes PenKid as Relevant Functional Biomarker for Sepsis-Associated Acute Kidney Injury

SphingoTec Appoints Dr. Florian Uhle as Medical Director

Liberation from renal replacement therapy and early initiation to be supported by the kidney function biomarker Proenkephalin A 119-159 (penKid)

Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)

Interdepartmental testing of the kidney function biomarker penKid in routine care at Heidelberg University Hospital and the Heidelberg Kidney Center

Medical thought leaders in critical care aim to advance precision medicine using biomarker-based approaches

Endothelial function biomarker bioactive Adrenomedullin (bio-ADM) enables triage of sepsis patients in the emergency department

SphingoTec appoints Jörg Menten as CEO to accelerate commercialization and global growth

Biomarker-guided trial led by University Hospital Hamburg-Eppendorf (UKE) opens new avenues for personalized medicine in COVID-19

The Biomarkers bio-ADM and DPP3 Complement Post-Cardiac Surgery Diagnostics to Early Detect Organ Failure

SphingoTec and Rivaara Labs Close Exclusive Distribution Agreement for Point of Care Diagnostics in India

Proenkephalin (penKid) sheds light on the diagnostic blind spots in assessing acute kidney injury in children

SphingoTec Appoints Jörg Menten to Leadership Team as Chief Commercial Officer to Drive New Business Growth

SphingoTec’s innovative biomarkers to enable personalized medicine in septic organ failure

New data on innovative biomarkers used to guide the clinical management of septic patients

SphingoTec Appoints Dr. Gerald Möller as Chairman of the Advisory Board

SphingoTec Expands Management Team and Appoints new CFO

SphingoTec Accelerates Growth with Direct Sales

Endothelial Function Biomarker bio-ADM to Support Risk Stratification and Clinical Management of COVID-19 Patients

SphingoTec GmbH: New diagnostic tool for the management of patients with sepsis: Dipeptidyl Peptidase 3 (DPP3)

Two distinct pathways leading to the development of septic shock pave the way for personalized medicine in sepsis

Proenkephalin (penKid(R)) included in the ADQI consensus statements publication as functional kidney biomarker for the management of AKI patients

Uniklinik RWTH Aachen is the first hospital to implement SphingoTec’s innovative biomarkers in clinical routine with the aim of making intensive care diagnostics more precise

SphingoTec GmbH: SphingoTec, BHR Pharmaceuticals ink agreement for distribution of SphingoTec’s acute care portfolio in the UK and Ireland

SphingoTec’s kidney function biomarker penKid(R) accurately detects acute kidney injury in infants